661 related articles for article (PubMed ID: 31138318)
1. The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells.
Wang T; Wang D; Zhang L; Yang P; Wang J; Liu Q; Yan F; Lin F
J Exp Clin Cancer Res; 2019 May; 38(1):226. PubMed ID: 31138318
[TBL] [Abstract][Full Text] [Related]
2. The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors.
Izumchenko E; Chang X; Michailidi C; Kagohara L; Ravi R; Paz K; Brait M; Hoque MO; Ling S; Bedi A; Sidransky D
Cancer Res; 2014 Jul; 74(14):3995-4005. PubMed ID: 24830724
[TBL] [Abstract][Full Text] [Related]
3. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
Park KS; Raffeld M; Moon YW; Xi L; Bianco C; Pham T; Lee LC; Mitsudomi T; Yatabe Y; Okamoto I; Subramaniam D; Mok T; Rosell R; Luo J; Salomon DS; Wang Y; Giaccone G
J Clin Invest; 2014 Jul; 124(7):3003-15. PubMed ID: 24911146
[TBL] [Abstract][Full Text] [Related]
4.
Hu C; Zhou A; Hu X; Xiang Y; Huang M; Huang J; Yang D; Tang Y
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362025
[TBL] [Abstract][Full Text] [Related]
5. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
[TBL] [Abstract][Full Text] [Related]
6. KLF8 promotes cancer stem cell-like phenotypes in osteosarcoma through miR-429-SOX2 signaling.
Zhang L; Yang P; Liu Q; Wang J; Yan F; Duan L; Lin F
Neoplasma; 2020 May; 67(3):519-527. PubMed ID: 32122144
[TBL] [Abstract][Full Text] [Related]
7. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
[TBL] [Abstract][Full Text] [Related]
8. A microRNA signature of response to erlotinib is descriptive of TGFβ behaviour in NSCLC.
Krentz Gober M; Collard JP; Thompson K; Black EP
Sci Rep; 2017 Jun; 7(1):4202. PubMed ID: 28646226
[TBL] [Abstract][Full Text] [Related]
9. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
10. LncRNA FER1L4 induces apoptosis and suppresses EMT and the activation of PI3K/AKT pathway in osteosarcoma cells via inhibiting miR-18a-5p to promote SOCS5.
Ye F; Tian L; Zhou Q; Feng D
Gene; 2019 Dec; 721():144093. PubMed ID: 31473323
[TBL] [Abstract][Full Text] [Related]
11. EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition.
Sato F; Kubota Y; Natsuizaka M; Maehara O; Hatanaka Y; Marukawa K; Terashita K; Suda G; Ohnishi S; Shimizu Y; Komatsu Y; Ohashi S; Kagawa S; Kinugasa H; Whelan KA; Nakagawa H; Sakamoto N
Cancer Biol Ther; 2015; 16(6):933-40. PubMed ID: 25897987
[TBL] [Abstract][Full Text] [Related]
12. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.
Ahmad A; Maitah MY; Ginnebaugh KR; Li Y; Bao B; Gadgeel SM; Sarkar FH
J Hematol Oncol; 2013 Oct; 6(1):77. PubMed ID: 24199791
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-126 Inhibits Proliferation, Migration, Invasion, and EMT in Osteosarcoma by Targeting ZEB1.
Jiang R; Zhang C; Liu G; Gu R; Wu H
J Cell Biochem; 2017 Nov; 118(11):3765-3774. PubMed ID: 28379605
[TBL] [Abstract][Full Text] [Related]
15. Tumor-Targeted Nanoparticles Deliver a Vitamin D-Based Drug Payload for the Treatment of EGFR Tyrosine Kinase Inhibitor-Resistant Lung Cancer.
Liu C; Shaurova T; Shoemaker S; Petkovich M; Hershberger PA; Wu Y
Mol Pharm; 2018 Aug; 15(8):3216-3226. PubMed ID: 29902012
[TBL] [Abstract][Full Text] [Related]
16. miR-17-5p promotes proliferation and epithelial-mesenchymal transition in human osteosarcoma cells by targeting SRC kinase signaling inhibitor 1.
Zhao X; Xu Y; Sun X; Ma Y; Zhang Y; Wang Y; Guan H; Jia Z; Li Y; Wang Y
J Cell Biochem; 2019 Apr; 120(4):5495-5504. PubMed ID: 30302813
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-181c Suppresses the Biological Progression of Osteosarcoma via Targeting SMAD7 and Regulating Transforming Growth Factor-β (TGF-β) Signaling Pathway.
Fu Y; Tang Y; Wang J; Guo Z
Med Sci Monit; 2019 Jun; 25():4801-4810. PubMed ID: 31251735
[TBL] [Abstract][Full Text] [Related]
18. By targeting TRAF6, miR-140-3p inhibits TGF-β1-induced human osteosarcoma epithelial-to-mesenchymal transition, migration, and invasion.
Guo Q; Zhang N; Liu S; Pang Z; Chen Z
Biotechnol Lett; 2020 Nov; 42(11):2123-2133. PubMed ID: 32562135
[TBL] [Abstract][Full Text] [Related]
19. PHD3 Controls Lung Cancer Metastasis and Resistance to EGFR Inhibitors through TGFα.
Dopeso H; Jiao HK; Cuesta AM; Henze AT; Jurida L; Kracht M; Acker-Palmer A; Garvalov BK; Acker T
Cancer Res; 2018 Apr; 78(7):1805-1819. PubMed ID: 29339541
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of miR-23a increases the sensitivity of lung cancer stem cells to erlotinib through PTEN/PI3K/Akt pathway.
Han Z; Zhou X; Li S; Qin Y; Chen Y; Liu H
Oncol Rep; 2017 Nov; 38(5):3064-3070. PubMed ID: 28901474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
